Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 2/2009

01-04-2009 | Original Article

Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin’s lymphoma: comparison with serum soluble interleukin-2 receptor values

Authors: Mitsuaki Tatsumi, Hiroyuki Sugahara, Ichiro Higuchi, Hiroki Fukunaga, Hironobu Nakamura, Yuzuru Kanakura, Jun Hatazawa

Published in: International Journal of Clinical Oncology | Issue 2/2009

Login to get access
Metadata
Title
Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin’s lymphoma: comparison with serum soluble interleukin-2 receptor values
Authors
Mitsuaki Tatsumi
Hiroyuki Sugahara
Ichiro Higuchi
Hiroki Fukunaga
Hironobu Nakamura
Yuzuru Kanakura
Jun Hatazawa
Publication date
01-04-2009
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 2/2009
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-008-0823-x

Other articles of this Issue 2/2009

International Journal of Clinical Oncology 2/2009 Go to the issue

Introduction to Review Articles

Implementation and limitations of meta-analysis of randomized trials from the clinical biostatistician’s point of view

Review Article

The role of meta-analysis in cancer clinical trials

Original Article

Chemo-hyperthermic peritoneal perfusion (CHPP) for appendiceal pseudomyxoma peritonei

Case Report

Adenoendocrine cell carcinoma of the gallbladder clinically mimicking squamous cell carcinoma

Original Article

Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients

Original Article

Phase I study of amrubicin and vinorelbine in non-small cell lung cancer previously treated with platinum-based chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits